Momenta Pharmaceuticals Price-to-Tangible-Book Historical Data
The historical data trend for Momenta Pharmaceuticals's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Momenta Pharmaceuticals's Price-to-Tangible-Book
For the Drug Manufacturers - Specialty & Generic subindustry, Momenta Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Momenta Pharmaceuticals's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Momenta Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Momenta Pharmaceuticals's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Momenta Pharmaceuticals Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Momenta Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Momenta Pharmaceuticals (Momenta Pharmaceuticals) Business Description
Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MNTA has been successfully added to your 